Progress in Alzheimer’s and Parkinson’s Diseases

Front Matter....Pages i-xxiii
The Pathogenesis of Alzheimer’s Disease....Pages 1-5
Molecular and Cellular Abnormalities of Tau in Early Alzheimer’s Disease....Pages 7-11
Apoe and Memory in Alzheimer’s Disease....Pages 13-16
Divergent Metabolism of Apolipoproteins E3 and E4 by Cells....Pages 17-23
App, Apoe, and Presenilin Transgenics....Pages 25-30
Differential Susceptibility of Human Apolipoprotein E Isoforms to Oxidation and Consequences on their Interaction with Phospholipids....Pages 31-38
The Apolipoprotein E ε4 Allele....Pages 39-43
Apoptosis in Alzheimer’s Disease....Pages 45-51
Membrane Constituencies and Receptor Subtype Contribute to Age-Related Increases in Vulnerability to Oxidative Stress....Pages 53-58
Mitochondrial Dysfunction and Alzheimer’s Disease....Pages 59-66
Mitochondrial Dysfunction in Parkinson’s Disease....Pages 67-75
Neuronal Oxidative Stress is a Common Feature of Alzheimer’s and Parkinson’s Diseases....Pages 77-80
Common Mechanisms in Cell Cycle and Cell Death....Pages 81-87
Intracerebroventricular Administration of Beta-Amyloid Peptide (25-35) Induces Oxidative Stress and Neurodegeneration in Rat Brain....Pages 89-98
Molecular Characterization of the Neuroprotective Activity of Salicylates....Pages 99-103
N-Methyl(R)Salsolinol: A Neurotoxin Candidate to Induce Parkinson’s Disease Causes Apoptosis in Dopamine Cells....Pages 105-111
Age-Related Na,K-Atpase mRNA Expression and Alzheimer’s Disease....Pages 113-119
HB-GAM, a Novel Amyloid Associated Protein, is Present in Prion Related Disorders and other Cerebral Amyloidoses....Pages 121-131
Regulation of APP Metabolism by Protein Phosphorylation....Pages 133-140
Identification of Peptides Binding to Presenilin 1 by Screening of Random Peptide Display Libraries....Pages 141-147
Matrix-Metalloproteinases (MMPS) in Astroglial Cells....Pages 149-157
Polyamines and Related Compounds in Nerve Cell Death and Survival....Pages 159-162
Haloperidol Induces Neurotoxicity in Mouse Embryo Brain Tissue....Pages 163-169
Direct Evidence that Lactate is an Obligatory Aerobic Energy Substrate for Functional Recovery Posthypoxia in Vitro....Pages 171-176
Comparative Study of Antioxidants’ Action on Membrane-Bound Acetylcholinesterase (AChE) of Blood Erythrocytes and Brain Synaptosomes....Pages 177-181
Ultra-Low Doses of Antioxidant and Acetylcholine Modify the Lipid Phase and Kinetic Properties of Acetylcholinesterase in Murine Brain Membranes....Pages 183-186
Amyloid-β Hypothesis of Alzheimer’s Disease....Pages 187-190
Discovery and Characterization of Peptidoorganic Inhibitors of Amyloid β-Peptide Polymerization....Pages 191-195
Anthracyclines and Amyloidosis....Pages 197-204
The Amino Terminus of the β-Amyloid Peptide Contains an Essential Epitope for Maintaining its Solubility....Pages 205-211
Animal Models of Amyloid Aggregation and Deposition....Pages 213-221
The Conformations of Tau Protein and its Aggregation into Alzheimer Paired Helical Filaments....Pages 223-233
Role of Neurofibrillary Degeneration in Alzheimer’s Disease....Pages 235-240
Cytoskeletal Protein Gene Expression after Neuronal Injury Recapitulates Developmental Patterns....Pages 241-249
Hyperphosphorylation of Tau in Apolipoprotein E-Deficient Mice....Pages 251-256
Aβ Induces Cell Death in Pc12 Cells and Tau-Transfected Cho Cells, but only Tau Phosphorylation in Pc12 Cells....Pages 257-263
Different Cognitive Profiles on Memory Tests in Parkinson’s Disease and Alzheimer’s Disease....Pages 265-270
Neuropsychological Subtypes and Rate of Progression in Alzheimer’s Disease....Pages 271-275
Brain Banking in Aging and Dementia Research-the Amsterdam Experience....Pages 277-285
Insulin, Insulin Receptors, and Igf-I Receptors in Post-Mortem Human Brain in Alzheimer’s Disease....Pages 287-292
Demonstration of Aluminum in the Brain of Patients with Alzheimer’s Disease....Pages 293-300
Lipid Composition of Different Brain Regions in Patients with Alzheimer’s Disease and Multi-Infarct Dementia....Pages 301-307
Verbal and Motor Memory in Alzheimer’s Disease: Release from Proactive Inhibition....Pages 309-315
Cognitive and Non-Cognitive Symptoms in Senile Dementia....Pages 317-322
Dementia Associated Sleep Disorders....Pages 323-327
Freezing Phenomenon, the Fifth Cardinal Sign of Parkinsonism....Pages 329-335
Cognitive Impairment in Patients with Parkinsonism....Pages 337-341
Cognitive Impairment Without Dementia in Parkinson’s Disease....Pages 343-350
Neuroleptic Malignant Syndrome and Dementia with Lewy Bodies....Pages 351-357
Case Report on a Generalized Epilepsy in a Patient Suffering from Parkinson’s Disease....Pages 359-361
Pathophysiology of Hereditary Progressive Dystonia with Marked Diurnal Fluctuation-its Characteristics in Contrast to other Dopa-Responsive Disorders....Pages 363-370
Effects of Progressive Neurological Disease on Interpersonal Relations Between Patients and Family Members....Pages 371-376
Cognitive Deficits in Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Chorea....Pages 377-383
Recall of Ytzhak Rabin’s Assassination by Demented People....Pages 385-387
Study of Dementia in China....Pages 389-392
Genetic Aspects of Parkinson’s Disease....Pages 393-399
a Chromosome 6q-Linked Parkinsonism....Pages 401-406
Cytokines in Parkinson’s Disease....Pages 407-412
 N -Methyl( R )Salsolinol and ( R )Salsolinol N -Methyltransferase as Possible Pathogenic Factors in Parkinson’s Disease....Pages 413-420
Antioxidant and Cytoprotective Properties of Apomorphine....Pages 421-427
Toxicity of 1BnTIQ, Endogenous Amine in the Brain, in Mesencephalic Slice Culture....Pages 429-433
Dopaminergic Responsiveness of Hypokinesia but not of Rigidity and Tremor is Reduced in Fluctuating Parkinson’s Disease....Pages 435-438
Motor Fluctuation and Levodopa Absorption....Pages 439-444
The Rationale for Development of Cholinergic Therapies in ad....Pages 445-450
Dementia with Lewy Bodies....Pages 451-462
Nicotinic Receptors as a new Target for Treatment of Alzheimer’s Disease....Pages 463-468
S 12024-2, A Cognitive Enhancer, Interacts with Nicotinic Neurotransmission....Pages 469-476
Lewy Body Influence on Tacrine Efficacy....Pages 477-480
Tacrine Treatment in Parkinson’s Disease Dementia....Pages 481-486
App Localization and Trafficking in the Central Nervous System....Pages 487-494
The Cholinergic but not the Serotonergic Phenotype of Anew Neuronal Cell Line is Sensitive to β-Amyloid-Induced Toxicity....Pages 495-501
The Molecular Basis Underlying the Discrete Activation of Signal Transduction Pathways by Selective Muscarinic Agonists....Pages 503-508
Muscarinic Modulation of β-Amyloid Precursor Protein (βApp) Processing in Vitro and in Vivo....Pages 509-513
Ml Muscarinic Agonists: From Treatment Toward Delaying Progression of Alzheimer’s Disease....Pages 515-522
Crystallographic Studies on Complexes of Acetylcholinesterase with the Natural Cholinesterase Inhibitors Fasciculin and Huperzine A....Pages 523-530
What can be Learned from the use of HuAChE Mutants for Evaluation of Potential Alzheimer’s Drugs....Pages 531-539
Cholinesterases in Neurogenesis....Pages 541-549
The Non-Catalytic Role and Complex Management of Acetylcholinesterase in the Mammalian Brain Call for RNA-Based Therapies....Pages 551-555
Antisense Oligodeoxynucleotide Dependent Suppression of Acetylcholinesterase Expression Reduces Process Extension from Primary Mammalian Neurons....Pages 557-562
Tacrine Reduces the Secretion of Soluble Amyloid Beta-Peptides in a Neuroblastoma Cell Line....Pages 563-569
Cholinesterase Inhibitors for Alzheimer’s Disease Therapy....Pages 571-577
The Preclinical Pharmacology of Metrifonate, Along-Acting and Well Tolerated Cholinesterase Inhibitor for Alzheimer Therapy....Pages 579-585
Increase in Cerebral Blood Flow and Glucose Utilization in Beneficial Effect of a Cholinesterase Inhibitor, Ena713 in Alzheimer’s Disease....Pages 587-593
Quaternary-Lipophilic Carbamates with Blood Brain Barrier Permeability as Potential Drugs for Memory Impairment Associated with Cholinergic Deficiency....Pages 595-600
Characterization of C-10 Substituted Analogues of Huperzine A as Inhibitors of Cholinesterases....Pages 601-605
Functional Effects of GDNFon Dopamine Neurons in Animal Models of Parkinson’s Disease....Pages 607-614
Development and Uses of Small Molecule Ligands of TrkA Receptors....Pages 615-625
Molecular Cloning, Transient Expression, and Neurotrophic Effect for DA Neurons of Human Brain Derived Neurotrophic Factor....Pages 627-633
Preventive Treatment of Alzheimer’s Disease....Pages 635-642
Clinical Aspects of Neurotransplantation of Embryonal Brain Tissue....Pages 643-646
Gene Therapy of a Rodent Model of Parkinson’s Disease using Adeno-Associated Virus (AAV) Vectors....Pages 647-652
S 17092-1, A New Post-Proline Cleaving Enzyme Inhibitor: Memory Enhancing Effects and Substance P Neuromodulatory Activity....Pages 653-660
Age Dependence of Muscarinic Plasticity in the Rat Hippocampus....Pages 661-666
Models of Cholinergic Degeneration: AF64A and 192-IgG-Saporin....Pages 667-674
Molecular Mechanisms of AF64A Toxicity in the Cholinergic Neuron....Pages 675-680
The AF64A Model of Cholinergic Hypofunction....Pages 681-686
Effect of AF64A/NGF Treatment on ChAT MRNA Expression in the Septo-Hippocampal Pathway and Striatum....Pages 687-694
Induction, Secretion, and Pharmacological Regulation of β-App in Animal Model Systems....Pages 695-698
Anapsos Improves Learning and Memory in Rats with βA(1–28) Deposits Into the Hippocampus....Pages 699-703
 In Vivo Neurotoxicity of β-Amyloid 1–40 in the Rat Hippocampus....Pages 705-709
Impairments of Cholinergic But Not of Nigrostriatal Dopaminergic Projections in Apolipoprotein E Deficient Mice....Pages 711-716
Interval Hypoxic Training Prevents Oxidative Stress in Striatum and Locomotor Disturbances in a Rat Model of Parkinsonism....Pages 717-723
An α 2 -Adrenoceptor Agonist, Clonidine, Disrupts Attentional Performance....Pages 725-731
Functional Neuroimaging Reveals Decline From Premorbid Functioning in AD....Pages 733-738
Novel Phenyltropanes: Affinity to Monoamine Transporters in Rat Forebrain....Pages 739-745
APP Isoforms in Platelets....Pages 747-750
Neuropsychological and Positron Emission Tomographic Comparisons of Alzheimer’s, Multi-Infarct, and Parkinson’s Disease Dementias....Pages 751-756
α1-Antichymotrypsin and Apolipoprotein E Polymorphism in Alzheimer’s Disease....Pages 757-764
Influence of the Apoe Genoptype on Serum Apoe Levels in Alzheimer’s Disease Patients....Pages 765-771
Development of a Specific Diagnostic Test for Measurement of β-Amyloid (1-42) [βA 4 (l-42)] in CSF....Pages 773-778
Indices of Oxidative Stress in the Peripheral Blood of De Novo Patients With Parkinson’s Disease....Pages 779-785
Acylphosphatase Levels In Alzheimer’s Disease Cultured Skin Fibroblasts....Pages 787-791
Centromeric Disturbances Affecting All Chromosomes of Cultured Lymphocytes Obtained From Alzheimer’s Disease Patients....Pages 793-798
APOE Genotype-Related Blood Pressure in Senile Dementia....Pages 799-803
Apolipoprotein E (ApoE) Phenotype in Alzheimer’s Disease, Vascular Dementia and Parkinson’s Disease with and Without Dementia in Northern Ireland....Pages 805-810
Changes in Cerebral Blood Flow Associated with Disease Staging and Apoe Genotyping in Patients with Senile Dementia....Pages 811-815
Apolipoprotein E ε4 Allele Does Not Influence the Development of Dementia in Parkinsonian Patients....Pages 817-821
A Simple Procedure of Immunochemical Detection of Amyloid β Proteins using Milligram Amounts of Brain Tissues of Patients with Alzheimer’s Disease....Pages 823-828
Bridging Studies in Alzheimer’s Disease....Pages 829-832
How Can we Improve the Drug Development Process in Alzheimer’s Disease?....Pages 833-839
Trial to Prevent Neurodegeneration in Persons Genetically Predisposed to Alzheimer’s Disease....Pages 841-845
Delaying Endpoints in Alzheimer’s Disease and Mild Cognitive Impairment....Pages 847-849
Current Neurotransmitter Strategies in AD Drug Development....Pages 851-859
Harmonization of Drug Approval Guidelines in Alzheimer’s and Parkinson’s Diseases....Pages 861-865
Back Matter....Pages 867-888